Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nonacog beta pegol - Novo Nordisk

Next Previous
Drug Profile

Nonacog beta pegol - Novo Nordisk

Alternative Names: 40K PEG-rFIX; Glycopegylated rFIX - Novo Nordisk; La-rFIX derivative - Novo Nordisk; N9 GP; NN 7999; NNC-0156-0000-0009; REBINYN; Rebinyn; Refixia

Latest Information Update: 19 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihaemorrhagics; Blood coagulation factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia B

Most Recent Events

  • 17 Nov 2023 Novo Nordisk completes phase III paradigm™5 trial for Haemophilia B (in children) in USA, Canada, Brazil, United Kingdom, Italy, Croatia, France, Germany, Japan, Malaysia, Taiwan (IV) (NCT01467427) (EudraCT2011-000826-31)
  • 21 Feb 2023 Registered for Haemophilia B (Prevention) in USA (IV)
  • 27 Oct 2022 Novo Nordisk completes the phase III paradigm™6 trial for Haemophilia B (Prevention, In neonates, In infants, In children) in USA, Algeria, Argentina, Australia, Austria, Canada, France, Germany, Israel, Italy, Japan, Malaysia, Romania, Spain, Netherlands, Taiwan, Thailand, United Kingdom (IV) (NCT02141074) (EudraCT2012-004867-38)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top